160 related articles for article (PubMed ID: 34677008)
41. Lipoprotein A, combined with alanine aminotransferase and aspartate aminotransferase, contributes to predicting the occurrence of NASH: a cross-sectional study.
Zhang Y; He H; Zeng YP; Yang LD; Jia D; An ZM; Jia WG
Lipids Health Dis; 2020 Jun; 19(1):134. PubMed ID: 32527258
[TBL] [Abstract][Full Text] [Related]
42. Interrogation of selected genes influencing serum LDL-Cholesterol levels in patients with well characterized NAFLD.
Vilar-Gomez E; Gawrieh S; Liang T; McIntyre AD; Hegele RA; Chalasani N
J Clin Lipidol; 2021; 15(2):275-291. PubMed ID: 33454241
[TBL] [Abstract][Full Text] [Related]
43. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis.
Ampuero J; Pais R; Aller R; Gallego-Durán R; Crespo J; García-Monzón C; Boursier J; Vilar E; Petta S; Zheng MH; Escudero D; Calleja JL; Aspichueta P; Diago M; Rosales JM; Caballería J; Gómez-Camarero J; Lo Iacono O; Benlloch S; Albillos A; Turnes J; Banales JM; Ratziu V; Romero-Gómez M;
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):216-225.e5. PubMed ID: 31195161
[TBL] [Abstract][Full Text] [Related]
44. Serum β-trophin level as a new marker for noninvasive assessment of nonalcoholic fatty liver disease and liver fibrosis.
Cengiz M; Ozenirler S; Kocabiyik M
Eur J Gastroenterol Hepatol; 2016 Jan; 28(1):57-63. PubMed ID: 26513612
[TBL] [Abstract][Full Text] [Related]
45. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
Castera L; Friedrich-Rust M; Loomba R
Gastroenterology; 2019 Apr; 156(5):1264-1281.e4. PubMed ID: 30660725
[TBL] [Abstract][Full Text] [Related]
46. VLDL (Very-Low-Density Lipoprotein)-Apo E (Apolipoprotein E) May Influence Lp(a) (Lipoprotein [a]) Synthesis or Assembly.
Croyal M; Blanchard V; Ouguerram K; Chétiveaux M; Cabioch L; Moyon T; Billon-Crossouard S; Aguesse A; Bernardeau K; Le May C; Flet L; Lambert G; Hadjadj S; Cariou B; Krempf M; Nobécourt-Dupuy E
Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):819-829. PubMed ID: 32078365
[TBL] [Abstract][Full Text] [Related]
47. Plasma Aldo-Keto Reductase Family 1 Member B10 as a Biomarker Performs Well in the Diagnosis of Nonalcoholic Steatohepatitis and Fibrosis.
Park A; Choi SJ; Park S; Kim SM; Lee HE; Joo M; Kim KK; Kim D; Chung DH; Im JB; Jung J; Shin SK; Oh BC; Choi C; Nam S; Lee DH
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563425
[TBL] [Abstract][Full Text] [Related]
48. Noninvasive Serum Fibrosis Markers are Associated with Coronary Artery Calcification in Patients with Nonalcoholic Fatty Liver Disease.
Song DS; Chang UI; Kang SG; Song SW; Yang JM
Gut Liver; 2019 Nov; 13(6):658-668. PubMed ID: 30970434
[TBL] [Abstract][Full Text] [Related]
49. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.
Krawczyk M; Rau M; Schattenberg JM; Bantel H; Pathil A; Demir M; Kluwe J; Boettler T; Lammert F; Geier A;
J Lipid Res; 2017 Jan; 58(1):247-255. PubMed ID: 27836992
[TBL] [Abstract][Full Text] [Related]
50. Hepatic and circulating levels of PCSK9 in morbidly obese patients: Relation with severity of liver steatosis.
Emma MR; Giannitrapani L; Cabibi D; Porcasi R; Pantuso G; Augello G; Giglio RV; Re NL; Capitano AR; Montalto G; Soresi M; Cervello M
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Dec; 1865(12):158792. PubMed ID: 32777481
[TBL] [Abstract][Full Text] [Related]
51. Measurements of serum procollagen-III peptide and M30 do not improve the diagnostic accuracy of transient elastography for the detection of hepatic fibrosis in patients with nonalcoholic fatty liver disease.
Ergelen R; Akyuz U; Aydin Y; Eren F; Yilmaz Y
Eur J Gastroenterol Hepatol; 2015 Jun; 27(6):667-71. PubMed ID: 25923941
[TBL] [Abstract][Full Text] [Related]
52. The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy.
Mikolasevic I; Domislovic V; Krznaric-Zrnic I; Krznaric Z; Virovic-Jukic L; Stojsavljevic S; Grgurevic I; Milic S; Vukoja I; Puz P; Aralica M; Hauser G
Medicina (Kaunas); 2022 Feb; 58(2):. PubMed ID: 35208576
[No Abstract] [Full Text] [Related]
53. Nonalcoholic fatty liver disease associated with metabolic syndrome: Influence of liver fibrosis stages on characteristics of very low-density lipoproteins.
Lucero D; Miksztowicz V; Gualano G; Longo C; Landeira G; Álvarez E; Zago V; Brites F; Berg G; Fassio E; Schreier L
Clin Chim Acta; 2017 Oct; 473():1-8. PubMed ID: 28802640
[TBL] [Abstract][Full Text] [Related]
54. A comparison of FibroMeter™ NAFLD Score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease.
Aykut UE; Akyuz U; Yesil A; Eren F; Gerin F; Ergelen R; Celikel CA; Yilmaz Y
Scand J Gastroenterol; 2014 Nov; 49(11):1343-8. PubMed ID: 25259621
[TBL] [Abstract][Full Text] [Related]
55. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography.
Imajo K; Kessoku T; Honda Y; Tomeno W; Ogawa Y; Mawatari H; Fujita K; Yoneda M; Taguri M; Hyogo H; Sumida Y; Ono M; Eguchi Y; Inoue T; Yamanaka T; Wada K; Saito S; Nakajima A
Gastroenterology; 2016 Mar; 150(3):626-637.e7. PubMed ID: 26677985
[TBL] [Abstract][Full Text] [Related]
56. Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population.
Wargny M; Ducluzeau PH; Petit JM; Le May C; Smati S; Arnaud L; Pichelin M; Bouillet B; Lannes A; Blanchet O; Lefebvre P; Francque S; Van Gaal L; Staels B; Vergès B; Boursier J; Cariou B
Atherosclerosis; 2018 Nov; 278():82-90. PubMed ID: 30261472
[TBL] [Abstract][Full Text] [Related]
57. MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease.
Costa-Silva L; Ferolla SM; Lima AS; Vidigal PVT; Ferrari TCA
Eur J Radiol; 2018 Jan; 98():82-89. PubMed ID: 29279175
[TBL] [Abstract][Full Text] [Related]
58. A case of hypocholesterolemia and steatosis in a carrier of a PCSK9 loss-of-function mutation and polymorphisms predisposing to nonalcoholic fatty liver disease.
Di Filippo M; Vokaer B; Seidah NG
J Clin Lipidol; 2017; 11(4):1101-1105. PubMed ID: 28711549
[TBL] [Abstract][Full Text] [Related]
59. Plasma Cytokeratin-18 Level As a Novel Biomarker for Liver Fibrosis in Children With Nonalcoholic Fatty Liver Disease.
Mandelia C; Collyer E; Mansoor S; Lopez R; Lappe S; Nobili V; Alkhouri N
J Pediatr Gastroenterol Nutr; 2016 Aug; 63(2):181-7. PubMed ID: 26835904
[TBL] [Abstract][Full Text] [Related]
60. Does the FT3-to-FT4 ratio easily predict the progression of NAFLD and NASH cirrhosis?
Türker F; Oral A; Şahin T; Türker BÇ; Koçak E; Ataoğlu HE; Ahbab S
J Int Med Res; 2021 Nov; 49(11):3000605211056841. PubMed ID: 34763561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
